88.93 +1.68 (1.93%)
After hours: 5:00PM EDT
|Bid||86.01 x 800|
|Ask||0.00 x 1000|
|Day's Range||86.63 - 88.43|
|52 Week Range||59.50 - 89.25|
|PE Ratio (TTM)||43.87|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||0.50 (0.57%)|
|1y Target Est||87.67|
LONDON, UK / ACCESSWIRE / June 19, 2018/ If you want a free Stock Review on ZTS sign up now at www.wallstequities.com/registration. Under evaluation this morning are these four stocks: Flexion Therapeutics Inc. (NASDAQ: FLXN), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), PetIQ Inc. (NASDAQ: PETQ), and Zoetis Inc. (NYSE: ZTS).
After looking at Zoetis Inc’s (NYSE:ZTS) latest earnings announcement (31 March 2018), I found it useful to revisit the company’s performance in the past couple of years and assess thisRead More...
LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want access to our free research report on Regeneron Pharma, Inc. (NASDAQ: REGN) ("Regeneron"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=REGN as the Company's latest news hit the wire. On June 06, 2018, the Company announced that it has inked a five-year collaboration deal with Zoetis Inc. (NYSE: ZTS), which is a global animal health Company. The deal is aimed at researching the use of Regeneron's monoclonal antibody therapeutics in animals, and discover new veterinary treatments.
After falling from $393 per share early this year to a recent low of $284 per share, analysts have begun pounding the table again for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). Regeneron is a biotech company known for drugs like Zaltrap, a cancer drug.
Zoetis Inc. (ZTS) will participate in the William Blair 2018 Growth Stock Conference on Tuesday, June 12, 2018, in Chicago, Ill. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services.
TARRYTOWN, N.Y. and PARSIPPANY, N.J., June 6, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Zoetis Inc. (ZTS) today announced a five-year collaboration to research the use of Regeneron's monoclonal antibody therapeutics in animals and discover new veterinary treatments. Under the terms of the agreement, Regeneron has granted Zoetis a license for its VelocImmune® antibody technology, which Zoetis will use to develop monoclonal antibodies modified for species-specific use in companion and livestock animals.
NEW YORK , June 5, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
I am going to run you through how I calculated the intrinsic value of Zoetis Inc (NYSE:ZTS) using the discounted cash flow (DCF) method. Anyone interested in learning a bitRead More...
Zoetis Inc (NYSE:ZTS) outperformed the Pharmaceuticals industry on the basis of its ROE – producing a higher 49.27% relative to the peer average of 12.26% over the past 12 months.Read More...
Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.
Post takeover of Abaxis' (ABAX) point-of-care diagnostic instruments, Zoetis expects the consolidated company's veterinary diagnostics category to speed up growth over the animal health industry.
Animal-health company Zoetis Inc. has agreed to buy Abaxis Inc., a maker of veterinary-diagnostics equipment, in a deal valued at about $2 billion. Zoetis has offered $83 a share in cash for Abaxis, about a 16% premium to Abaxis’s closing price Tuesday. The companies said Wednesday the deal would grow Zoetis’s presence in veterinary diagnostics, a sector that has had an annual compound growth rate of about 10% for the past three years.
Stocks rose on Wednesday, May 16, as investors traded cautiously on news that North Korea may cancel a planned summit with the United States and as government bond yields rose to multi-year highs amid renewed bets of faster inflation and quicker interest rate hikes from the Federal Reserve. North Korea has threatened to pull out of the June 12 meeting with President Donald Trump in Singapore if Washington insists on complete denuclearization for the rogue nation. "If the U.S. is trying to drive us into a corner to force our unilateral nuclear abandonment, we will no longer be interested in such dialogue and cannot but reconsider our proceeding to the DPRK-U.S. summit," North Korea said in a statement that was issued through its state broadcaster.
Moody's Investors Service commented that Zoetis Inc.'s (Zoetis, Baa1 stable) plans to acquire Abaxis, Inc. (unrated), for $2 billion is credit negative. There is no impact on Zoetis' Baa1 senior unsecured rating, Prime-2 short term rating, or the stable rating outlook. For additional information please refer to Moody's Issuer Comment on Zoetis Inc. available on www.moodys.com.
The deal announced Wednesday reflects Zoetis' expectation that the diagnostics category will grow at a faster pace than the broader animal health industry. Abaxis — which makes blood and urine tests to predict, detect and treat diseases such as heartworm, Lyme disease or tick-borne infections — will also help its New Jersey-based acquirer bolster its presence in overseas markets. Zoetis faces much lesser competition internationally than in the United States, its Chief Executive Officer Juan Alaix said on a conference call with analysts.
The deal will have Zoetis Inc spending a total of $2 billion in cash to acquire Abaxis Inc. This values ABAX stock at $83 per share. Zoetis Inc. says that its acquisition of Abaxis Inc will allow it to strengthen its business in the veterinary diagnostics market.
Zoetis Inc. ( ZTS), a top animal healthcare company, plans to buy veterinary diagnostics company Abaxis Inc. ( ABAX) in a $2.0-billion deal, the companies announced today. New Jersey-based Zoetis, which has more than $5 billion in annual revenue, is aiming for a larger market share in the veterinary diagnostics services industry, which is currently a small portion of its total sales. It expects Abaxis, which provides tools to detect animal diseases, will add to its earnings by next year.
Zoetis Inc (NYSE: ZTS), an animal health company, announced a deal to acquire Abaxis Inc (NASDAQ: ABAX), a developer of portable blood analysis systems used in human or veterinary patient care, for $83 per share in cash or a total of $2 billion. This represented a 15.8 percent premium over the $71.75 percent at which Abaxis closed Tuesday's session. Reacting to the announcement, shares of Abaxis were rallying 14.91 percent to $82.45 in pre-market trading.
Animal health company Zoetis Inc said on Wednesday it would buy Abaxis Inc, a maker of veterinary diagnostic instruments, for about $1.9 billion in cash to bolster its position in the fast-growing diagnostics market. Zoetis has offered Abaxis $83 per share, a premium of 15.7 percent to its closing price on Tuesday. The transaction will add to Zoetis' earnings next year and the company will fund the purchase through cash and new debt.